Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Abstract 4194: Inhibiting PELP1 signaling enhances the therapeutic effectiveness of topoisomerase inhibitors in triple-negative breast cancer

Khaled Mohamed Nassar, John R. Sanchez, Durga Meenakshi Panneerdoss, Behnam Ebrahimi, Xue Yang, Uday P. Pratap, Megharani Mahajan, Salvador Cardenas Alejo, Abhi Katabathina, Panneerdoss Subbarayalu, Daohong Zhou, Rajeshwar R. Tekmal, Gangadhara Reddy Sareddy, Manjeet K. Rao, Suryavathi Viswanadhapalli, Ratna K. Vadlamudi

Cancer Res (2025) 85 (8_Supplement_1): 4194.

https://doi.org/10.1158/1538-7445.AM2025-4194

Published: 21 April 2025

View articletitled, Abstract 4194: Inhibiting PELP1 signaling enhances the therapeutic effectiveness of topoisomerase inhibitors in triple-negative breast cancer

Journal Articles

Abstract 5989: Investigating the potential of EC359 in inducing ferroptosis for the treatment of type I and type II endometrial cancers

Emily J. Aller, Xue Yang, Megharani R. Mahajan, Behnam Ebrahimi, Paulina Ramirez, Hareesh B. Nair, Edward Kost, Ratna K. Vadlamudi, Suryavathi Viswanadhapalli

Cancer Res (2025) 85 (8_Supplement_1): 5989.

https://doi.org/10.1158/1538-7445.AM2025-5989

Published: 21 April 2025

View articletitled, Abstract 5989: Investigating the potential of EC359 in inducing ferroptosis for the treatment of type I and type II endometrial cancers

Journal Articles

Abstract 3756: Optimization of the LIPA targeting agent for the treatment of ovarian cancer

Cancer Res (2025) 85 (8_Supplement_1): 3756.

https://doi.org/10.1158/1538-7445.AM2025-3756

Published: 21 April 2025

View articletitled, Abstract 3756: Optimization of the LIPA targeting agent for the treatment of ovarian cancer

Journal Articles

Abstract 4315: PELP1 oncogene targeted therapy for the treatment of ovarian cancer

Gaurav Sharma, Behnam Ebrahimi, Arhan Rao, William C. Arnold, Hariprasad Vankayalapati, Rajeshwar R. Tekmal, Suryavathi Viswanadhapalli, Ratna K. Vadlamudi

Cancer Res (2025) 85 (8_Supplement_1): 4315.

https://doi.org/10.1158/1538-7445.AM2025-4315

Published: 21 April 2025

View articletitled, Abstract 4315: PELP1 oncogene targeted therapy for the treatment of ovarian cancer

Journal Articles

Abstract 1630: Targeting the LIF/LIFR axis reduces the progression of inflammatory breast cancer by promoting ferroptosis

Bianca A. Romo, Zenaida Fuentes, Lois Randolph, Megharani Mahajan, Emily J. Aller, Behnam Ebrahimi, Bindu Santhamma, Hareesh B. Nair, Christoforos Thomas, Ratna K. Vadlamudi, Suryavathi Viswanadhapalli

Cancer Res (2025) 85 (8_Supplement_1): 1630.

https://doi.org/10.1158/1538-7445.AM2025-1630

Published: 21 April 2025

View articletitled, Abstract 1630: Targeting the LIF/LIFR axis reduces the progression of inflammatory breast cancer by promoting ferroptosis

Journal Articles

Abstract 5985: Low-grade serous ovarian cancer is effectively treated with a combination of trametinib and LIFR inhibitor therapeutics

William C. Arnold, Durga Meenakshi Panneerdoss, Suryavathi Viswanadhapalli, Behnam Ebrahimi, Hareesh B. Nair, Ratna K. Vadlamudi, Yasmin A. Lyons

Cancer Res (2025) 85 (8_Supplement_1): 5985.

https://doi.org/10.1158/1538-7445.AM2025-5985

Published: 21 April 2025

View articletitled, Abstract 5985: Low-grade serous ovarian cancer is effectively treated with a combination of trametinib and LIFR inhibitor therapeutics

Journal Articles

Abstract PO3-26-10: Small molecule inhibitor of PELP1 exhibit cytotoxic effects on breast cancer cells by blocking ribosome biogenesis

Xue Yang, Khaled Mohamed Nassar, Uday Pratap, Rahul Gopalam, Behnam Ebrahimi, Durga Meenakshi Panneerdoss, Xiaonan Li, Yaxia Yuan, Daohong Zhou, Gangadhara R. Sareddy, Rajeshwar R. Tekmal, Manjeet Rao, Suryavathi Viswanadhapalli, Ratna Vadlamudi

Cancer Res (2024) 84 (9_Supplement): PO3-26-10.

https://doi.org/10.1158/1538-7445.SABCS23-PO3-26-10

Published: 02 May 2024

View articletitled, Abstract PO3-26-10: Small molecule inhibitor of PELP1 exhibit cytotoxic effects on breast cancer cells by blocking ribosome biogenesis

Journal Articles

Abstract 2099: PELP1 inhibition enhances the therapeutic efficacy of topoisomerase inhibitors in triple-negative breast cancer

Khaled Mohamed Nassar, John R. Sanchez, Durga Meenakshi Panneerdoss, Behnam Ebrahimi, Yang Xue, Uday P. Pratap, Salvador C. Alejo, Gangadhara R. Sareddy, Suryavathi Viswanadhapalli, Ratna K. Vadlamudi

Cancer Res (2024) 84 (6_Supplement): 2099.

https://doi.org/10.1158/1538-7445.AM2024-2099

Published: 22 March 2024

View articletitled, Abstract 2099: PELP1 inhibition enhances the therapeutic efficacy of topoisomerase inhibitors in triple-negative breast cancer

Journal Articles

Abstract 5998: Pharmacological inhibition of the LIF-LIFR autocrine loop reveals vulnerability of ovarian cancer to ferroptosis

Cancer Res (2024) 84 (6_Supplement): 5998.

https://doi.org/10.1158/1538-7445.AM2024-5998

Published: 22 March 2024

View articletitled, Abstract 5998: Pharmacological inhibition of the LIF-LIFR autocrine loop reveals vulnerability of ovarian cancer to ferroptosis

Journal Articles

Abstract 2100: Novel LIPA targeted therapy for treating inflammatory breast cancer

Zenaida Fuentes, Rahul Gopalam, Bianca A. Romo, Khaled Mohamed Nassar, Xue Yang, Behnam Ebrahimi, Paulina Ramirez, Chia-Yuan Chen, Scott Elmore, Harika Nagandla, Uday Pratap, Christoforos Thomas, Suryavathi Viswanadhapalli, Jung-Mo Ahn, Ganesh Raj, Ratna K. Vadlamudi

Cancer Res (2024) 84 (6_Supplement): 2100.

https://doi.org/10.1158/1538-7445.AM2024-2100

Published: 22 March 2024

View articletitled, Abstract 2100: Novel LIPA targeted therapy for treating inflammatory breast cancer

Journal Articles

Abstract 394: Preclinical evaluation of ERX-208, a potent inducer of ER stress for the treatment of ovarian cancer

Cancer Res (2024) 84 (6_Supplement): 394.

https://doi.org/10.1158/1538-7445.AM2024-394

Published: 22 March 2024

View articletitled, Abstract 394: Preclinical evaluation of ERX-208, a potent inducer of ER stress for the treatment of ovarian cancer

Journal Articles

Abstract 4688: EC359, A new therapeutic drug for the treatment of low grade serous ovarian cancer

Yasmin Lyons, William Cole Arnold, Behnam Ebrahimi, Bindu Santhamma, Edward R. Kost, Hareesh B. Nair, Suryavathi Viswanadhapalli, Ratna K. Vadlamudi

Cancer Res (2024) 84 (6_Supplement): 4688.

https://doi.org/10.1158/1538-7445.AM2024-4688

Published: 22 March 2024

View articletitled, Abstract 4688: EC359, A new therapeutic drug for the treatment of low grade serous ovarian cancer

Journal Articles

Abstract 4813: ERX-208 as a novel therapeutic for treating ovarian cancer by enhancing endoplasmic reticulum stress

Cancer Res (2023) 83 (7_Supplement): 4813.

https://doi.org/10.1158/1538-7445.AM2023-4813

Published: 04 April 2023

View articletitled, Abstract 4813: ERX-208 as a novel therapeutic for treating ovarian cancer by enhancing endoplasmic reticulum stress

Journal Articles

Abstract 4966: Targeting LIF/LIFR autocrine loops with EC359 in ovarian cancer: A novel LIFR targeted therapy

Behnam Ebrahimi, Suryavathi Viswanadhapalli, Uday P. Pratap, Rahul Gopalam, Xue Yang, Bindhu Santhamma, Swapna Konda, Xiaonan Li, Hui Yan, Gangadhara R. Sareddy, Zhenming Xu, Edward R. Kost, Rajeshwar R. Tekmal, Hareesh B. Nair, Ratna K. Vadlamudi

Cancer Res (2023) 83 (7_Supplement): 4966.

https://doi.org/10.1158/1538-7445.AM2023-4966

Published: 04 April 2023

View articletitled, Abstract 4966: Targeting LIF/LIFR autocrine loops with EC359 in ovarian cancer: A novel LIFR targeted therapy

Journal Articles

Abstract 3986: Novel LIPA targeted therapy for treating ovarian cancer

Cancer Res (2023) 83 (7_Supplement): 3986.

https://doi.org/10.1158/1538-7445.AM2023-3986

Published: 04 April 2023

View articletitled, Abstract 3986: Novel LIPA targeted therapy for treating ovarian cancer

Journal Articles

A First-in-Class Inhibitor of ER Coregulator PELP1 Targets ER⁺ Breast Cancer

Cancer Res (2022) 82 (20): 3830–3844.

https://doi.org/10.1158/0008-5472.CAN-22-0698

Published: 17 October 2022

View articletitled, A First-in-Class Inhibitor of ER Coregulator PELP1 Targets ER+ Breast Cancer

Includes: Supplementary data

Journal Articles

Abstract 648: A novel small molecule targeting oncogenic PELP1 demonstrates anti-tumor activity in wild-type and mutant ER-positive breast cancer

Kristin Ann Altwegg, Monica Mann, Dimple Chakravarty, Zexuan Liu, Junhao Liu, Uday P. Pratap, Behnam Ebrahimi, John R. Sanchez, Ben H. Park, Hariprasad Vankayalapati, Gangadhara R. Sareddy, Suryavathi Viswanadhapalli, Ratna K. Vadlamudi

Cancer Res (2022) 82 (12_Supplement): 648.

https://doi.org/10.1158/1538-7445.AM2022-648

Published: 15 June 2022

View articletitled, Abstract 648: A novel small molecule targeting oncogenic PELP1 demonstrates anti-tumor activity in wild-type and mutant ER-positive breast cancer

Journal Articles

Abstract P5-10-01: Leukemia inhibitory factor receptor inhibition reduces obesity driven progression of triple negative breast cancer

Suryavathi Viswanadhapalli, Uday P Pratap, Behnam Ebrahimi, Logan Blankenship, Jaitri Joshi, Zexuan Liu, Kristin A Altwegg, Xiaonan Li, Gangadhara R Sareddy, Bindu Santhamma, Swapna Konda, Manjeet Rao, Edward Kost, Rajeshwar R Tekmal, Hareesh B Nair, Ratna K Vadlamudi

Cancer Res (2022) 82 (4_Supplement): P5-10-01.

https://doi.org/10.1158/1538-7445.SABCS21-P5-10-01

Published: 15 February 2022

View articletitled, Abstract P5-10-01: Leukemia inhibitory factor receptor inhibition reduces obesity driven progression of triple negative breast cancer

Journal Articles

Abstract 1253: Therapeutic targeting of endometrial cancer with novel LIFR inhibitor EC359

Weiwei Tang, Kumaraguruparan Ramasamy, Sureshkumar M. Pillai, Bindu Santhamma, Swapna Konda, Prabhakar P. Vekata, Logan Blankenship, Junhao Liu, Zexuan Liu, Kristin A. Altwegg, Behnam Ebrahimi, Uday P. Pratap, Xiaonan Li, Edward Kost, Gangadhara R. Sareddy, Ratna K. Vadlamudi, Hareesh B. Nair, Rajeshwar R. Tekmal, Suryavathi Viswanadhapalli

Cancer Res (2021) 81 (13_Supplement): 1253.

https://doi.org/10.1158/1538-7445.AM2021-1253

Published: 01 July 2021

View articletitled, Abstract 1253: Therapeutic targeting of endometrial cancer with novel LIFR inhibitor EC359

Journal Articles

Abstract 733: Significance of PELP1/SETDB1 axis in endocrine therapy resistance

Zexuan Liu, Junhao Liu, Weiwei Tang, Uday P. Pratap, Kristin A. Altwegg, Behnam Ebrahimi, Xiaonan Li, Gangadhara R. Sareddy, Suryavathi Viswanadhapalli, Ratna K. Vadlamudi

Cancer Res (2021) 81 (13_Supplement): 733.

https://doi.org/10.1158/1538-7445.AM2021-733

Published: 01 July 2021

View articletitled, Abstract 733: Significance of PELP1/SETDB1 axis in endocrine therapy resistance

Update search

NARROW

Format

Journal

Article Type

Issue Section

Date

Availability

Abstract 4194: Inhibiting PELP1 signaling enhances the therapeutic effectiveness of topoisomerase inhibitors in triple-negative breast cancer

Abstract 5989: Investigating the potential of EC359 in inducing ferroptosis for the treatment of type I and type II endometrial cancers

Abstract 3756: Optimization of the LIPA targeting agent for the treatment of ovarian cancer

Abstract 4315: PELP1 oncogene targeted therapy for the treatment of ovarian cancer

Abstract 1630: Targeting the LIF/LIFR axis reduces the progression of inflammatory breast cancer by promoting ferroptosis

Abstract 5985: Low-grade serous ovarian cancer is effectively treated with a combination of trametinib and LIFR inhibitor therapeutics

Abstract PO3-26-10: Small molecule inhibitor of PELP1 exhibit cytotoxic effects on breast cancer cells by blocking ribosome biogenesis

Abstract 2099: PELP1 inhibition enhances the therapeutic efficacy of topoisomerase inhibitors in triple-negative breast cancer

Abstract 5998: Pharmacological inhibition of the LIF-LIFR autocrine loop reveals vulnerability of ovarian cancer to ferroptosis

Abstract 2100: Novel LIPA targeted therapy for treating inflammatory breast cancer

Abstract 394: Preclinical evaluation of ERX-208, a potent inducer of ER stress for the treatment of ovarian cancer

Abstract 4688: EC359, A new therapeutic drug for the treatment of low grade serous ovarian cancer

Abstract 4813: ERX-208 as a novel therapeutic for treating ovarian cancer by enhancing endoplasmic reticulum stress

Abstract 4966: Targeting LIF/LIFR autocrine loops with EC359 in ovarian cancer: A novel LIFR targeted therapy

Abstract 3986: Novel LIPA targeted therapy for treating ovarian cancer

A First-in-Class Inhibitor of ER Coregulator PELP1 Targets ER⁺ Breast Cancer

Abstract 648: A novel small molecule targeting oncogenic PELP1 demonstrates anti-tumor activity in wild-type and mutant ER-positive breast cancer

Abstract P5-10-01: Leukemia inhibitory factor receptor inhibition reduces obesity driven progression of triple negative breast cancer

Abstract 1253: Therapeutic targeting of endometrial cancer with novel LIFR inhibitor EC359

Abstract 733: Significance of PELP1/SETDB1 axis in endocrine therapy resistance

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only